# Enact Holdings, Inc. (ACT) — Financial Analysis

**Exchange:** Nasdaq  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-03  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ACT/thesis · /stocks/ACT/memo

## Financial Snapshot

---
source: coverage-next-full
step: 04
ticker: ACT
company: Enact Holdings, Inc.
created: 2026-06-03
---

### Step 04 — Financial Quality & Adversarial Sweep: Enact Holdings, Inc. (ACT)

*Note: Earnings call transcript analysis was not performed. This is the filings-and-consensus path.*

---

#### 1. Financial Statement Quality Assessment

##### Income Statement Quality

**Revenue recognition:** Net premiums are earned over the policy period (pro-rata). This is straightforward for PMI — no channel-stuffing or pull-forward dynamics are possible since policies are individually underwritten. [S1]

**Adjusted Operating Income (Non-GAAP):** Enact's primary management metric is "Adjusted Operating Income" which excludes:
- Net realized investment gains/losses (volatile, non-core)
- Net loss on debt extinguishment (one-time)
- Tax-effected adjustments

FY2024: GAAP Net Income $688M vs. Adj. OI $718M — a $30M difference driven by realized investment losses. This is a defensible exclusion for an insurer; investment gains/losses are largely mark-to-market noise for a buy-and-hold portfolio. [S1]

**Loss ratio nuance — the "gross vs. net" issue:** The reported 4% loss ratio (FY2024) reflects:
- Gross new delinquency losses: ~$290M (FY2024 accident year)
- Prior-year reserve releases: ~($258M)
- Net loss provision: $32M (primary + run-off)

The $258M of prior-year releases is real economic value — these are accurate reserve adjustments as actual claims came in below prior estimates during a benign housing environment. However, this dynamic creates opacity: in a deteriorating credit environment, not only do new delinquency losses rise, but prior-year releases would disappear, creating a 2x earnings headwind. [S1]

**Effective Tax Rate:** Stable at 21.6-21.8% over FY2022-FY2024. ACT is part of the Genworth consolidated tax group; tax consolidation provides efficiency but creates contingent liability. [S1]

##### Balance Sheet Quality

| Item | Assessment |
|------|------------|
| Investment portfolio (~$5.4B) | High quality: U.S. Treasuries, agency MBS, investment-grade corporates. Duration 4.1 years — well-matched to liabilities. Unrealized losses normalized as rates peaked. |
| Loss reserves | Actuarially determined; recent favorable development is genuine (low unemployment, home price appreciation). Reserve adequacy is the key uncertainty in a stress scenario. |
| Debt structure | Single tranche: $750M 2029 Notes at ~6.7%. No near-term maturities. Clean. |
| Equity composition | ~$5B equity vs. $743M debt (0.15x debt/equity). Fortress balance sheet. |
| Deferred Acquisition Costs (DAC) | $9.7M amortization in FY2024 — immaterial. PMI doesn't have complex DAC issues. |

##### Cash Flow Quality

FCF ≈ Operating Cash Flow for an insurer (no meaningful CapEx). OCF grew from $560M (FY2022) → $632M (FY2023) → $686M (FY2024) → $724M (FY2025). [S3]

**OCF vs. Net Income convergence:** OCF/Net Income = 99.7% in FY2024 ($686M / $688M). This is an extremely high earnings quality ratio — virtually all reported net income converts to cash. For an insurer, this is expected (no inventory, no receivables buildup), but confirms financial quality. [S3]

---

#### 2. Statement Adjustments

| Adjustment | Impact | Reason |
|-----------|--------|--------|
| Remove realized investment losses | +$23M pre-tax | Mark-to-market noise; portfolio is not held for trading |
| Remove debt extinguishment charge | +$11M pre-tax | One-time; not recurring |
| **Adjusted Operating Income** | **$718M** | Used as core earnings proxy |
| Normalize loss ratio to 12% | -$78M pre-tax | Stress-test; 4% is benign cycle; 12% is conservative normalized |
| **Normalized Adj. OI** | **~$640M** | Cyclically adjusted base |

---

#### 3. Adversarial Research Sweep

##### Short Interest & Short Theses
ACT is lightly shorted — public float is only ~18-19% of shares outstanding (Genworth holds ~81%), meaning the tradeable float is approximately $1.1B. [S5] Short interest data is limited due to the low float. No prominent public short thesis identified in the research. The main bear arguments circulating among analysts are:

1. **Housing correction risk:** The bear case is structural — loss ratios of 3-4% in 2023-2024 are historically anomalous (lowest since the early 2000s bubble run-up). In the 2007-2010 cycle, PMI industry loss ratios exceeded 100%. Enact did not exist as a public company in that cycle, but its predecessor (Genworth Mortgage Insurance) sustained significant losses. [S2]

2. **Genworth overhang:** Genworth holds ~81% of ACT shares. Genworth has historically been a "distressed" parent (Long-Term Care liabilities, prior failed sale processes). Market discounts ACT for governance risk and Genworth's inability to provide strategic flexibility to ACT. [S1]

3. **PMIERs tightening:** The 2024 update (effective September 2026) tightens Available Asset definitions. Enact's 170% sufficiency provides buffer, but any further regulatory tightening could constrain capital returns. [S1]

4. **Premium rate compression:** Net earned premium rate has declined from 40 bps (FY2022) to 36 bps (FY2024) — a structural compression driven by competitive pricing. If rates decline to 32-33 bps, it would offset IIF growth and put premium revenue under pressure. [S1]

##### Legal & Regulatory Investigations
- No material pending litigation identified in FY2024 10-K beyond ordinary course mortgage insurance claims. [S1]
- No SEC investigations, class action litigation, or regulatory enforcement actions identified. [S1]
- ACT did face legacy litigation related to Genworth's pre-IPO mortgage insurance operations; these are substantially resolved. [S2]

##### Accounting Red Flags
- **None identified.** The financial statements are clean. Revenue recognition is straightforward. Reserve methodology is standard actuarial practice (IBNR + case reserves). The only complexity is the prior-year reserve release dynamic, which is disclosed, not obscured.
- SBC grew from $1.5M (FY2021) to $19M (FY2025) as post-IPO equity compensation programs matured. This represents ~2.7% of net income — not excessive but worth monitoring. [S3]

---

#### 4. Peer Comparison Snapshot

| Metric | ACT (FY2024) | MTG | RDN | ESNT | NMIH |
|--------|-------------|-----|-----|------|------|
| Loss Ratio | 4% | ~5% | ~6% | ~2% | ~3% |
| Expense Ratio | 23% | ~22% | ~25% | ~20% | ~29% |
| Net Income Margin | 57% | ~55% | ~50% | ~60% | ~50% |
| PMIERs Sufficiency | ~170% | ~170% | ~165% | ~180% | ~160% |
| P/B | ~1.1x | ~1.4x | ~1.3x | ~2.5x | ~1.5x |
| P/E (trailing) | ~8.9x | ~9x | ~9x | ~14x | ~11x |

*ACT trades at a discount to the peer group on P/B, primarily due to Genworth overhang constraining institutional ownership. ESNT commands a premium on lower-leverage business model and higher ROE.*

*Sources: [S4] [S5] [S9]*

---

#### Source Index

| # | Description |
|---|-------------|
| S1 | 10-K FY2024 — sec_filings/10K_FY2024_summary.md |
| S2 | 10-K FY2023 — sec_filings/10K_FY2023_summary.md |
| S3 | XBRL — xbrl/xbrl_summary.md |
| S4 | StockAnalysis — other/stockanalysis_summary.md |
| S5 | Consensus — other/consensus.md |
| S9 | Competitive landscape — industry/competitive_landscape.md |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ACT/fundamental

## Navigation

- Overview: /stocks/ACT
- Financials (this page): /stocks/ACT/financials
- Thesis: /stocks/ACT/thesis
- Investment Memo: /stocks/ACT/memo
- Coverage universe: /stocks